|
 |
|
May 16-19, 2004, Crystal Gateway Marriott,
Arlington, VA |
|
|
|
PROGRAM:
WEDNESDAY,
MAY 19TH |
| 7:00AM-11:00AM |
CONTRIBUTED
POSTER PRESENTATIONS VIEWING – SESSION II |
| 8:00AM-9:00AM |
CONTRIBUTED
PODIUM PRESENTATIONS – SESSION III |
| |
Research studies on the
following topics will be presented:
|
Prescribing Studies |
|
RX1
CLAIM-BASED DRUG
WASTAGE ESTIMATION: HOW HIDDEN REFILL BEHAVIOR CAN HELP
Xiao Q, Marks AS
Caremark Inc, Northbrook, IL, USA
RX2
PREVALENCE AND
CORRELATES OF POTENTIALLY INAPPROPRIATE PRESCRIBING AMONG THE AMBULATORY
ELDERLY IN 2001
Viswanathan H, Bharmal M, Thomas III J
Purdue University, West Lafayette, IN, USA
RX3
EVALUATING CLINICAL AND
FINANCIAL OUTCOMES ASSOCIATED WITH A RETROSPECTIVE DRUG UTILIZATION REVIEW
PROGRAM
Lee KY, Zajack L, Berdovich S, Bertram C,
Bundek N
Walgreens Health Initiatives, Deerfield, IL, USA
RX4
A DYNAMIC MODEL OF
BUDGET IMPACT ANALYSES
Han S1, Shih YCT2
1Rice University, Houston, TX, USA; 2The University of
Texas, M.D. Anderson Cancer Center, Houston, TX, USA |
|
Adherence/Compliance |
|
AC1
CAPTURING
PATIENT-REPORTED COMPLIANCE DATA IN A NINE-COUNTRY PRODUCT REGISTRY USING MEMS CAP DEVICES
Steffan P, Becker R, Sama P
Ovation Research Group, Highland Park, IL, USA
AC2
COMPARING
PATIENT-REPORTED MEDICATION COMPLIANCE WITH ELECTRONICALLY MONITORED
MEDICATION COMPLIANCE IN A 12-MONTH INTERNATIONAL REGISTRY
Steffan P, Becker R, Sama P
Ovation Research Group, Highland Park, IL, USA
AC3
COMPARISION OF
ADHERENCE TO ANTIHYPERTENSIVES IN A MANAGED CARE POPULATION.
Naik RK1, Borrego ME1, Gupchup
GV1, D'Angio R2, Sabrsula S3
1University of New Mexico, Albuquerque, NM, USA; 2Pfizer
Inc, Albuquerque, NM, USA; 3Firstcare MCO, Albuquerque, NM, USA
AC4
CLINICAL AND ECONOMIC
OUTCOMES OF NON-ADHERENCE TO HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN
PATIENTS WITH HIV
Munakata J1, Benner JS1,
Becker SL2, Dezii CM3, Hazard EH1,
Tierce JC1
1ValueMedics Research, LLC, Arlington, VA, USA; 2Pacific
Horizon Medical Group, Inc, San Francisco, CA, USA; 3Bristol-Myers
Squibb, Plainsboro, NJ, USA
|
|
Pharmacoepidemiology |
|
PE1
ASSESSING EFFECTIVENESS
IN THE PRESENCE OF TREATMENT SWITCHING: DATA FROM AN EFFECTIVENESS STUDY OF ANTIPSYCHOTICS
Faries D1, Nyhuis A1, Tunis SL1,
Hernan M2
1Eli Lilly and Company, Indianapolis, IN, USA; 2Harvard
School of Public Health, Boston, MA, USA
PE2
THE EFFECTS OF
ANTIDEPRESSANT DRUGS ON THE RISK OF COLORECTAL CANCER: A POPULATION-BASED
CASE-CONTROL STUDY
Xu W, Tamim H, Shapiro S, Collet JP
McGill University, Montreal, Quebec, Canada
PE3
COMORBIDITY INFLUENCE
INDEX
Stockdale WA, Brixner DI
University of Utah, Salt Lake City, UT, USA
PE4
AN AUTOMATED METHOD TO
INFER MORBIDITY DESCRIPTIONS FROM PATIENT PHARMACY PROFILES
Prasad BN,PD, Huang XPD
Ingenix, Eden Prairie, MN, USA
|
|
Outcomes
and Preferences |
|
OP1
IS THE CURRENT METHOD
OF VALUING HEALTH OUTCOMES IN COST-EFFECTIVENESS ANALYSIS VALID?
O'Sullivan A1, Thompson D1,
Weinstein M2
1Innovus Research (US) Inc, Medford, MA, USA; 2Innovus
Research Inc. and Harvard School of Public Health, Boston, MA, USA
OP2
COMPARISON OF DISCRETE
CHOICE EXPERIMENT (DCE) WITH VISUAL ANALOG SCALING (VAS) METHODS FOR
ESTIMATING PREFERENCES FOR PHYSICAL DISABILITY STATES
Banks JL1, Netten A2, Ryan M3,
Watson V4, Salas M5
1University of Kent at Canterbury, Lincoln, MA, USA; 2University
of Kent at Canterbury, Canterbury, Kent, United Kingdom; 3University
of Aberdeen, Aberdeen, United Kingdom; 4University of Aberdeen
Medical School, Aberdeen, United Kingdom; 5Erasmus University
Medical School, Rotterdam, Netherlands
OP3
UNDERSTANDING THE
CHARACTERISTICS OF NON TRADERS IN TTO UTILITY ELICITATION
Miller LANup>, Mody R1, Singer ME2
1West Virginia University, Morgantown, WV, USA; 2Case
Western Reserve University School of Medicine, Cleveland, OH, USA
OP4
DEVELOPMENT AND
VALIDATION OF A PATIENT-REPORTED USEFULNESS SCALE TO EVALUATE ANTIEPILEPTIC
PHARMACOTHERAPY IN PATIENTS WITH EPILEPSY
Brown LM, Mulani P, Cifaldi M, Ashraf T
Abbott Laboratories, Abbott Park, IL, USA |
|
| 9:00AM-9:15AM |
BREAK |
| 9:15AM-10:15AM |
CONTRIBUTED PODIUM PRESENTATIONS – SESSION IV
Pharmacoeconomics/health economic, quality-of-life, and outcomes research
study results for the following diseases will be presented:
|
Diabetes |
|
DB1
THE IMPACT OF USING
EITHER THE FRAMINGHAM OR THE UNITED KINGDOM PROSPECTIVE DIABETES STUDY RISK
FORMULAE IN DIABETES HEALTH ECONOMICS MODELING.
Palmer AJ1, Roze S2, Lammert M3,
Valentine WJ1, Nicklasson L4
1CORE Center for Outcomes Research, Binningen/Basel, Baselland,
Switzerland; 2Novo Nordisk Pharmaceuticals Inc, Princeton, NJ,
USA
DB2
THE
ECONOMIC BURDEN OF TYPE 2 DIABETES MANAGEMENT BY ETHNIC GROUP IN THE TEXAS
MEDICAID POPULATION
Lee WC1, Stephens JM1, Tran KT1,
Wang Q1, Dirani RG2, Pashos CL3
1Abt Associates Inc,
Bethesda, MD, USA; 2Glaxo
Smith Kline, Philadelphia, PA; 3Abt
Associates Inc, Cambridge, MA, USA
DB3
OUTCOMES ASSOCIATED
WITH THE INTRODUCTION OF THIAZOLIDINEDIONE THERAPY IN ELDERLY PATIENTS WITH
TYPE 2 DIABETES MELLITUS: A RETROSPECTIVE DATA ANALYSIS
Balkrishnan R1, Rajagopalan R2,
Camacho F3, Anderson R3
1University of Texas School of Public Health, Houston, TX, USA;
2Takeda Pharmaceuticals North America, Inc, Lincolnshire, IL,
USA; 3Wake Forest University School of Medicine, Winston-Salem,
NC, USA
DB4
DRIVERS OF TREATMENT
PREFERENCE AMONG INDIVIDUALS WITH TYPE-2 DIABETES
McHorney C1, Hayes RP2, Bowman
L2, Myers J3
1Indiana University School of Medicine, Regenstrief Institute for
Health Care, Roudebush VA Medical Center, Indianapolis, IN, USA; 2Eli
Lilly & Company, Indianapolis, IN, USA; 3Roudebush VA Medical
Center, Indianapolis, IN, USA
|
|
Mental
Health |
|
MH1
AN ECONOMIC ANALYSIS OF
ANTIPSYCHOTIC TREATMENT FOR SCHIZOPHRENIA
Lui G1, Sun S1, Christensen D1,
Zhao Z2
1University of North Carolina at Chapel Hill, Chapel Hill, NC,
USA; 2Eli Lilly and Company, Indianapolis, IN, USA
MH2
IMPACT OF OPEN ACCESS
TO ATYPICAL ANTIPSYCHOTICS IN CALIFORNIA MEDICAID
Ahn J, McCombs JS
University of Southern California, Los Angeles, CA, USA
MH3
COST-EFFECTIVENESS OF
METHYLPHENIDATE OROS FOR ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD): AN
EVALUATION FROM THE PERSPECTIVE OF THE UK NATIONAL HEALTH SERVICE (NHS)
Schlander M
University of Witten/Herdecke & University of Applied Sciences Ludwigshafen,
Ludwigshafen am Rhein, Germany
MH4
ASSESSMENT OF HEALTH
STATE UTILITIES FOR ATTENTION-DEFICIT/HYPERACTIVITY DISORDER IN CHILDREN
USING PARENT-BASED STANDARD GAMBLE SCORES
Secnik K1, Cottrell S2, Matza
L3, Edgell E4, Aristides M5,
Tilden D2, Burridge J5, Mannix S6
1Eli Lilly and Company, Indianapolis, IN, USA; 2M-TAG
Pty Ltd., London, England; 3MEDTAP International, Bethesda, MD,
USA; 4Lilly Research Centre, Windlesham, United Kingdom; 5M-TAG
Limited, London, United Kingdom; 6MEDTAP International, Inc,
Bethesda, MD, USA
|
|
Neurological Disorders/Migraines |
|
ND1
ESTIMATING
COST-EFFECTIVENESS OF DRUGS THAT DELAY DISABILITY PROGRESSION IN MULTIPLE
SCLEROSIS USING NET BENEFIT REGRESSION MODEL METHODS
Brown MG1, Hoch JS2,
MacKinnon-Cameron D1
1Dalhousie University, Halifax, NS, Canada; 2University
of Western Ontario, London, ON, Canada
ND2
COST-EFFECTIVENESS OF
MIGRAINE PREVENTION: RESULTS FROM A MODEL OF TOPIRAMATE TREATMENT
Brown J1, Papadopoulos G2,
Neumann P3, Friedman M1, Menzin J1
1Boston Health Economics, Inc, Waltham, MA, USA; 2Johnson
& Johnson Pharmaceutical Services, Raritan, NJ, USA; 3Harvard
School of Public Health, Boston, MA, USA
ND3
MEDICAL SERVICES
UTILIZATION FOR PATIENTS WITH PARKINSON’S DISEASE IN A STATE MEDICAID
PROGRAM
Kamat S, Smith MJ
West Virginia University, Morgantown, WV, USA
ND4
BURDEN OF ILLNESS IN ALZHEIMER’S DISEASE IN THE UNITED KINGDOM
Livingston Gp>1, Katona C2, Roch B3
1University College London, London, United Kingdom; 2University
of Kent at Canterbury, Kent, United Kingdom; 3H. Lundbeck A/S,
Paris, France |
|
Health
Policy Evaluation |
|
HP1
EVALUATION OF GENERIC DISPENSING INCENTIVE PROGRAM (GDIP)
Hong SH
University of Arkansas for Medical Sciences, Little Rock, AR, USA
HP2
THE EFFECT OF MEDICAID COVERAGE DECISIONS ON
NON-SEDATING ANTIHISTAMINE UTILIZATION AND SPENDING FOLLOWING
OVER-THE-COUNTER AVAILABILITY OF LORATADINE
Hansen RA, Trygstad TK
University of North Carolina - Chapel Hill, Chapel Hill, NC, USA
HP3
EFFECT OF COPAY INCREASE ON FOUR MEASURES OF
COMPLIANCE: A NATURAL EXPERIMENT
Meissner B, Shinogle J, Kozma C, Shah M,
Franklin M
University of South Carolina, Columbia, SC, USA
HP4
CHALLENGES FOR EXAMINING THE ECONOMICS OF
PHARMACOGENOMICS
Phillips KA, Van Bebber SL, Veenstra DL
University of California San Francisco, San Francisco, CA, USA
|
|
| 10:45AM-11:00AM |
ISPOR CONTRIBUTED RESEARCH AWARDS PRESENTATION |
|
11:00AM-12:30PM |
THIRD PLENARY SESSION |
| |
THE $64,000 QUESTION: WHAT ARE WE WILLING TO PAY FOR A QALY?
Moderator:
Peter Neumann ScD,
Associate Professor of Policy and Decision Sciences, Harvard School of
Public Health, Boston, MA, USA
Speakers: James Hammitt PhD,
Professor of Economics & Decision Sciences, Harvard School of Public Health,
Boston, MA, USA; Reed Johnson PhD,
Principal Economist and Senior Fellow, RTI - Health Solutions, Research
Triangle Park, NC USA; Cam Donaldson MSc, PhD,
Professor of Health Economics,
University of Newcastle upon Tyne, Newcastle, United Kingdom
• New OMB guidance on QALYs
• Should we monetize QALYs?
• Research agenda for WTP and QALYs |
|
9th Annual International Meeting Main Page
|
|
